Latest news about Bafna Pharmaceuticals
Bafna Pharmaceuticals
174.58
-19.39(-10.00%)
Company Performance:
View Company Insights1D-10.00%
1M+32.26%
6M+24.45%
1Y+135.92%
5Y+22.21%
More news about Bafna Pharmaceuticals
27Mar 26
Bafna Pharmaceuticals Appoints Internal and Cost Auditors for FY 2026-27
Bafna Pharmaceuticals Limited's board meeting on March 27, 2026, approved the appointment of M/s. K.S. Rao & Co., Chartered Accountants as Internal Auditor and M/s. N. Sivashankaran & Co., Cost Accountants as Cost Auditor for Financial Year 2026-2027. Both firms bring extensive experience in their respective domains, with appointments effective from April 1, 2026, to March 31, 2027. The decisions were made in compliance with SEBI regulations, ensuring proper governance and auditing oversight for the upcoming financial year.
24Mar 26
Bafna Pharmaceuticals Clarifies Recent Share Price Movement as Market-Driven
Bafna Pharmaceuticals Limited issued a clarification on March 24, 2026, regarding recent share price movement following inquiries from BSE and NSE. The company stated it is unaware of any specific events causing the price fluctuations, attributing them to general market conditions and investor sentiment. The pharmaceutical company emphasized its continued compliance with SEBI disclosure requirements under Regulation 30.
11Feb 26
Bafna Pharmaceuticals Reports Strong Q3 FY26 Performance with 93.87% Profit Growth
Bafna Pharmaceuticals Limited reported strong Q3 FY26 results with revenue of ₹3,828.58 lakhs, up 15.36% YoY, and net profit of ₹183.69 lakhs, representing 93.87% growth from Q3 FY25. Nine-month performance showed revenue of ₹10,837.80 lakhs with net profit surging 193.88% to ₹835.06 lakhs. The company faces regulatory challenges including GST demands totaling ₹566.56 lakhs but remains confident of favorable outcomes through legal appeals.
23Jan 26
Bafna Pharmaceuticals Receives Credit Rating Outlook Upgrade from ICRA Limited
Bafna Pharmaceuticals Limited received a credit rating outlook upgrade from ICRA Limited on January 23, 2026, with the outlook revised from Stable to Positive. The rating agency reaffirmed the company's long-term rating at [ICRA] BB+ (Positive) and short-term rating at [ICRA] A4+ for total bank loan facilities worth Rs. 50.00 crores. The upgrade covers various banking facilities including term loans, cash credit, and letter of credit facilities primarily with ICICI Bank Limited.
12Nov 25
Bafna Pharmaceuticals Reports Revenue Growth and Profit Decline in Q2 FY2026
Bafna Pharmaceuticals Limited released its Q2 FY2026 results, showing a 2.44% increase in revenue to INR 3,546.82 crore, but a 7.79% decrease in net profit to INR 312.49 crore compared to Q2 FY2025. The company's total assets grew by 21.58% to INR 16,068.27 crore. The auditor's report highlighted issues with outstanding foreign currency receivables and an income tax refund adjustment under legal proceedings. Despite challenges, the company maintains steady revenue growth in the pharmaceutical sector.
12Aug 25
Bafna Pharmaceuticals Reports Strong Q1 Results, Announces Key Leadership Changes
Bafna Pharmaceuticals Limited reported strong Q1 FY2026 results with a net profit of ₹338.89 lakhs, compared to a loss in the previous year. Revenue from operations increased by 4.02% to ₹3,462.40 lakhs. The company announced its 30th AGM for September 19, 2025, and approved re-appointments of two Independent Directors and the CEO. The Nomination and Remuneration Committee was reconstituted. Bafna Pharmaceuticals also achieved the prescribed Minimum Public Shareholding and completed the sale of assets from its Madhavaram manufacturing unit.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,779.00
(-0.55%)
6,753.00
(+3.56%)
4,472.90
(+1.42%)
1,105.60
(+1.66%)
1,376.50
(-0.82%)
1,268.50
(-0.56%)
2,264.20
(+0.43%)
2,391.00
(+1.43%)
1,449.00
(-0.19%)
1,424.40
(+1.40%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
